Physician profile
Renae Mcelrath
NPI 1639848492
$855.30
in general payments reported to CMS, 2019-2025
16 companies · $42.41 in 2025
The $42.41 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.36 · 2022: $441 · 2023: $277 · 2024: $54.18 · 2025: $42.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $373.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $342.98 | 2022-2024 | |
| Glaxosmithkline, LLC. | $64.40 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Antares Pharma, INC. | $58.54 | 2022-2023 | Nocdurna, Xyosted, Tlando |
| Corcept Therapeutics | $57.22 | 2024-2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $55.85 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $47.66 | 2021-2022 | |
| Novo Nordisk INC | $40.10 | 2022-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $37.03 | 2021-2022 | |
| Nevro Corp. | $26.01 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.36 | 2023 | Jardiance |
| Amgen INC. | $22.22 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.87 | 2022 | |
| Avion Pharmaceuticals | $18.49 | 2023 | Balcoltra |
| Merck Sharp & Dohme LLC | $16.77 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.00 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $10.80 | 2024 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renae Mcelrath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.